Product Code:457644
Published Date: Feb 08,2023
Pages: 87
Region: Global
Category: Medical Devices & Consumables
PDF DOWNLOAD
GET FREE SAMPLE
CUSTOMIZE REQUEST
PDF DOWNLOAD
GET FREE SAMPLE
CUSTOMIZE REQUEST
Provide comprehensive and accurate analysis and reports according to your exact requirements
Overactive bladder (OAB) is a bladder disorder that results in an abnormal urge to urinate, urinary frequency, and nocturia (voiding at night). Some patients may also experience urinary incontinence (involuntary loss of bladder control). This report only focuses on the treatment drugs and Device. LPI (LP Information)' newest research report, the “Overactive Bladder Treatment Industry Forecast” looks at past sales and reviews total world Overactive Bladder Treatment sales in 2022, providing a comprehensive analysis by region and market sector of projected Overactive Bladder Treatment sales for 2023 through 2029. With Overactive Bladder Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Overactive Bladder Treatment industry. This Insight Report provides a comprehensive analysis of the global Overactive Bladder Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Overactive Bladder Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Overactive Bladder Treatment market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Overactive Bladder Treatment and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Overactive Bladder Treatment. The global Overactive Bladder Treatment market size is projected to grow from US$ 4989.1 million in 2022 to US$ 6182.8 million in 2029; it is expected to grow at a CAGR of 3.1% from 2023 to 2029. Global Overactive Bladder Treatment key players include Allergan, Astellas Pharma, Pfizer, Johnson & Johnson, Medtronic, etc. Global top five manufacturers hold a share about 90%. United States is the largest market, with a share about 60%, followed by Europe, with a share about 15 percent. In terms of product, Drugs is the largest segment, with a share about 95%. And in terms of application, the largest application is Idiopathic Overactive Bladder, followed by Neurogenic Overactive Bladder. This report presents a comprehensive overview, market shares, and growth opportunities of Overactive Bladder Treatment market by product type, application, key players and key regions and countries. Market Segmentation: Segmentation by type Drugs Device Segmentation by application Idiopathic Overactive Bladder Neurogenic Overactive Bladder This report also splits the market by region: Americas United States Canada Mexico Brazil APAC China Japan Korea Southeast Asia India Australia Europe Germany France UK Italy Russia Middle East & Africa Egypt South Africa Israel Turkey GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration. Allergan Astellas Pharma Pfizer Johnson & Johnson Medtronic KYORIN Pharmaceutical